ScholarIQanswers from OpenAlex & ORCID
Maura N. Dickler
ResearcherPublications, citations & collaboration network
Maura N. Dickler is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Maura N. Dickler have?
ScholarIQindexed works
Maura N. Dickler has 359 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Maura N. Dickler have?
ScholarIQcitation count
Maura N. Dickler has 17,923 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Maura N. Dickler?
ScholarIQh-index
Maura N. Dickler has an h-index of 58 in OpenAlex.
What is the i10-index of Maura N. Dickler?
ScholarIQi10-index
Maura N. Dickler has an i10-index of 124 in OpenAlex.
What is the ORCID of Maura N. Dickler?
ScholarIQorcid
The ORCID for Maura N. Dickler is on the source record.
What is the OpenAlex record for Maura N. Dickler?
ScholarIQopenalex
The OpenAlex for Maura N. Dickler is on the source record.
What are the most-cited papers on Maura N. Dickler?
ScholarIQmost cited works
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Kathy D. Miller, Molin Wang, Julie R. Gralow, Maura N. Dickler, Melody Cobleigh, Edith A. Perez, Tamara Shenkier, David Cella, Nancy E. Davidson
Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer
Kathy D. Miller, Linnea Chap, Frankie A. Holmes, Melody Cobleigh, P. Kelly Marcom, Louis Fehrenbacher, Maura N. Dickler, Beth Overmoyer, James D. Reimann, Amy P. Sing, Virginia K. Langmuir, Hope S. Rugo
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Pedram Razavi, Matthew T. Chang, Guotai Xu, Chaitanya Bandlamudi, Dara S. Ross, Neil Vasan, Yanyan Cai, Craig M. Bielski, Mark T.A. Donoghue, Philip Jonsson, Alexander Penson, Ronglai Shen, Fresia Pareja, Ritika Kundra, Sumit Middha, Michael L. Cheng, Ahmet Zehir, Cyriac Kandoth, Ruchi Patel, Kety Huberman, Lillian M. Smyth, Komal Jhaveri, Shanu Modi, Tiffany A. Traina, Chau T. Dang, Wen Zhang, Britta Weigelt, Bob T. Li, Marc Ladanyi, David M. Hyman, Nikolaus Schultz, Mark E. Robson, Clifford A. Hudis, Edi Brogi, Agnès Viale, Larry Norton, Maura N. Dickler, Michael F. Berger, Christine A. Iacobuzio–Donahue, Sarat Chandarlapaty, Maurizio Scaltriti, Jorge S. Reis‐Filho, David B. Solit, Barry S. Taylor, José Baselga
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer
Maura N. Dickler, Sara M. Tolaney, Hope S. Rugo, Javier Cortés, Véronique Dièras, Debra A. Patt, Hans Wildiers, Clifford A. Hudis, Joyce O’Shaughnessy, Esther Zamora, Denise A. Yardley, Martin Frenzel, Andrew Koustenis, José Baselga
Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
Hope S. Rugo, R. Bryan Rumble, Erin Macrae, Debra L. Barton, Hannah Connolly, Maura N. Dickler, Lesley Fallowfield, Barbara Fowble, James N. Ingle, Mohammad Jahanzeb, Stephen Johnston, Larissa A. Korde, James Khatcheressian, Rita S. Mehta, Hyman B. Muss, Harold J. Burstein